- Conditions
- Abdominal Obesity
- Interventions
- Tesamorelin, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atrial Flutter
- Interventions
- Vernakalant Injection 20 mg/mL
- Drug
- Lead sponsor
- Advanz Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 5
- States / cities
- Sacramento, California • Lansing, Michigan • Richmond, Virginia + 1 more
- Conditions
- Atrial Fibrillation
- Interventions
- Vernakalant Injection 20 mg/mL
- Drug
- Lead sponsor
- Advanz Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sacramento, California • Orlando, Florida + 7 more
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Healthy, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Tirzepatide, Placebo, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 11,850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- IGF-1, Placebo/saline
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervical Dystonia
- Interventions
- botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
- Biological · Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Dementia, Alzheimer's Disease
- Interventions
- Aripiprazole, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 14
- States / cities
- Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more
- Conditions
- Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
- Interventions
- NVG-291
- Drug
- Lead sponsor
- NervGen Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Migraine Headache
- Interventions
- Erenumab 70 mg, Erenumab 140 mg, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 32
- States / cities
- Cerritos, California • Colton, California • Los Angeles, California + 28 more
- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Osteoarthritis, Total Knee Replacement
- Interventions
- Ropivacaine injection, Saline Injection, Total Knee Arthroplasty
- Drug · Procedure
- Lead sponsor
- OrthoCarolina Research Institute, Inc.
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- ACTH, Placebo
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more
- Conditions
- Osteoarthritis
- Interventions
- Placebo saline injection, Ropivicaine 0.5%
- Other · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- COVID-19
- Interventions
- INB03, Placebo
- Drug
- Lead sponsor
- Inmune Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Bone morphogenetic protein 7, Placebo
- Drug
- Lead sponsor
- Stryker Biotech
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 25
- States / cities
- Glendale, Arizona • Tucson, Arizona • Palo Alto, California + 20 more
- Conditions
- Parkinson's Disease
- Interventions
- LY3962681, Placebo (aCSF)
- Drug · Other
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Englewood, Colorado • New Haven, Connecticut • Naples, Florida + 4 more
- Conditions
- Sepsis, Disseminated Intravascular Coagulation
- Interventions
- ART-123, placebo
- Drug
- Lead sponsor
- Artisan Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 46 more
- Conditions
- Type I Diabetes
- Interventions
- Exenatide (Bydureon®), Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
- Conditions
- Metabolic Dysfunction Associated Steatohepatitis
- Interventions
- Survodutide, Placebo matching survodutide
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 126
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
- Conditions
- Obesity
- Interventions
- AMG 598, Placebo, Liraglutide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide Nasal Spray, Placebo, Semaglutide Injection
- Drug
- Lead sponsor
- Shanghai World Leader Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey